Gil Blum
Stock Analyst at Needham
(4.46)
# 1,248
Out of 5,082 analysts
725
Total ratings
36.9%
Success rate
10.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gil Blum
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARTV Artiva Biotherapeutics | Downgraded: Hold | n/a | $4.27 | - | 18 | Oct 27, 2026 | |
| RXRX Recursion Pharmaceuticals | Reiterated: Buy | $8 | $4.05 | +97.53% | 31 | Oct 19, 2026 | |
| RCKT Rocket Pharmaceuticals | Reiterated: Buy | $9 | $2.45 | +267.35% | 52 | Oct 7, 2026 | |
| CRSP CRISPR Therapeutics AG | Reiterated: Buy | $82 | $51.47 | +59.32% | 44 | Oct 5, 2026 | |
| FATE Fate Therapeutics | Reiterated: Hold | n/a | $2.07 | - | 25 | Oct 5, 2026 | |
| NKTX Nkarta | Reiterated: Buy | $11 | $1.70 | +547.06% | 24 | Oct 5, 2026 | |
| AUTL Autolus Therapeutics | Reiterated: Buy | $10 | $1.55 | +545.16% | 53 | Oct 2, 2026 | |
| CELC Celcuity | Reiterated: Buy | $140 → $134 | $68.07 | +96.86% | 35 | Sep 30, 2026 | |
| IMMX Immix Biopharma | Reiterated: Buy | $21 → $30 | $8.05 | +272.67% | 3 | Sep 29, 2026 | |
| RNAC Cartesian Therapeutics | Reiterated: Buy | $40 | $6.46 | +519.20% | 38 | Sep 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | n/a | $18.89 | - | 57 | Sep 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 | $10.57 | +4.07% | 15 | Sep 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $44 | $10.12 | +334.78% | 7 | Sep 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.192 | - | 19 | Sep 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $56 | $19.11 | +193.04% | 1 | Aug 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $4.25 | +182.35% | 50 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $3 | $0.2917 | +928.45% | 35 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 | $6.19 | +206.95% | 8 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $75 | $31.96 | +134.67% | 23 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 | $1.15 | +247.83% | 36 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $34 | $26.70 | +27.34% | 48 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $5.77 | - | 28 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.26 | n/a | 25 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $5.72 | n/a | 15 | Dec 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 | $20.34 | n/a | 14 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $99.05 | n/a | 10 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.000001 | n/a | 6 | Jun 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 | $0.000001 | n/a | 5 | Apr 6, 2022 |
Artiva Biotherapeutics
Oct 27, 2026
Downgraded: Hold
Price Target: n/a
Current: $4.27
Upside: -
Recursion Pharmaceuticals
Oct 19, 2026
Reiterated: Buy
Price Target: $8
Current: $4.05
Upside: +97.53%
Rocket Pharmaceuticals
Oct 7, 2026
Reiterated: Buy
Price Target: $9
Current: $2.45
Upside: +267.35%
CRISPR Therapeutics AG
Oct 5, 2026
Reiterated: Buy
Price Target: $82
Current: $51.47
Upside: +59.32%
Fate Therapeutics
Oct 5, 2026
Reiterated: Hold
Price Target: n/a
Current: $2.07
Upside: -
Nkarta
Oct 5, 2026
Reiterated: Buy
Price Target: $11
Current: $1.70
Upside: +547.06%
Autolus Therapeutics
Oct 2, 2026
Reiterated: Buy
Price Target: $10
Current: $1.55
Upside: +545.16%
Celcuity
Sep 30, 2026
Reiterated: Buy
Price Target: $140 → $134
Current: $68.07
Upside: +96.86%
Immix Biopharma
Sep 29, 2026
Reiterated: Buy
Price Target: $21 → $30
Current: $8.05
Upside: +272.67%
Cartesian Therapeutics
Sep 29, 2026
Reiterated: Buy
Price Target: $40
Current: $6.46
Upside: +519.20%
Sep 28, 2026
Reiterated: Sell
Price Target: n/a
Current: $18.89
Upside: -
Sep 23, 2026
Reiterated: Buy
Price Target: $11
Current: $10.57
Upside: +4.07%
Sep 11, 2026
Reiterated: Buy
Price Target: $44
Current: $10.12
Upside: +334.78%
Sep 2, 2026
Downgraded: Hold
Price Target: n/a
Current: $0.192
Upside: -
Aug 21, 2026
Initiated Coverage: Buy
Price Target: $56
Current: $19.11
Upside: +193.04%
Aug 12, 2026
Reiterated: Buy
Price Target: $12
Current: $4.25
Upside: +182.35%
Aug 11, 2026
Reiterated: Buy
Price Target: $3
Current: $0.2917
Upside: +928.45%
Aug 7, 2026
Reiterated: Buy
Price Target: $19
Current: $6.19
Upside: +206.95%
Aug 6, 2026
Reiterated: Buy
Price Target: $75
Current: $31.96
Upside: +134.67%
Aug 5, 2026
Reiterated: Buy
Price Target: $4
Current: $1.15
Upside: +247.83%
Aug 4, 2026
Reiterated: Buy
Price Target: $34
Current: $26.70
Upside: +27.34%
Nov 7, 2025
Reiterated: Hold
Price Target: n/a
Current: $5.77
Upside: -
Oct 24, 2025
Rated: Hold
Price Target: n/a
Current: $1.26
Upside: n/a
Dec 27, 2024
Rated: Hold
Price Target: n/a
Current: $5.72
Upside: n/a
Dec 7, 2022
Reiterated: Buy
Price Target: $6
Current: $20.34
Upside: n/a
Aug 25, 2022
Rated: Hold
Price Target: n/a
Current: $99.05
Upside: n/a
Jun 3, 2022
Rated: Hold
Price Target: n/a
Current: $0.000001
Upside: n/a
Apr 6, 2022
Reiterated: Buy
Price Target: $6
Current: $0.000001
Upside: n/a